The company initiates a phase I/II clinical study in older adults with its quadrivalent nasal influenza vaccine candidate Immunose FLU.
The purpose of the study is to evaluate safety, tolerability, as well as serological and mucosal immune responses against four influenza antigens in older adults aged 50-75. Recruitment of subjects is ongoing and about 300 subjects will be divided into seven treatment groups. The study is planned to be conducted at five locations throughout Sweden during the present influenza season.
“It is exciting to take part in such an extensive study, designed to generate new knowledge in nasal vaccination and identify strategies to generate the broadest immune response possible in this target group,” says Kia Bengtsson, Director Clinical Development.
Results can be expected second half of 2018.
Photo of Kia Bengtsson: Eurocine Vaccine
